ABBV
WAITAbbVie Inc.
$263.30
+0.04%delayed
News – · Trend ▲ · inside triggers –
Expected move (1d)
▼ $257.21to$269.39 ▲
ATR ±$6.09 (+2.31%)Implied ±$11.20 (+4.25%)
Entry Reference
Price / prev close$263.30 / $263.20
Day range$262.75 – $267.47
52-wk range$187.62 – $267.47(95%)
Volume vs avg0.63×
ATR (14d)$6.09
MA 8 / 21$257.81 / $253.91
MA 50 / 200$236.37 / $224.45
Call ▲ / Put ▼ trigger$264.64 / $261.76
+1 / +2 ATR$269.39 / $275.47
-1 / -2 ATR$257.21 / $251.13
Support: 260.96 243.07 237.11
Resistance: -
Near-the-money contracts
exp 2026-07-31Calls
| Strike | Mark | IV | Δ | θ/day | OI |
|---|---|---|---|---|---|
| 257.5 | $9.55 | 66% | 0.70 | -1.22 | 299 |
| 260 | $7.70 | 62% | 0.62 | -1.25 | 958 |
| 262.5 | $6.30 | 62% | 0.54 | -1.29 | 63 |
| 265 | $4.97 | 61% | 0.45 | -1.26 | 414 |
| 267.5 | $3.93 | 60% | 0.36 | -1.18 | 112 |
| 270 | $2.96 | 59% | 0.28 | -1.04 | 409 |
Puts
| Strike | Mark | IV | Δ | θ/day | OI |
|---|---|---|---|---|---|
| 252.5 | $1.65 | 58% | -0.14 | -0.68 | 85 |
| 255 | $2.11 | 56% | -0.20 | -0.80 | 214 |
| 257.5 | $2.92 | 57% | -0.28 | -0.97 | 95 |
| 260 | $3.83 | 56% | -0.36 | -1.08 | 558 |
| 262.5 | $4.90 | 56% | -0.46 | -1.13 | 39 |
| 265 | $6.47 | 58% | -0.55 | -1.18 | 115 |
Δ = delta (≈ probability ITM), θ/day = daily time decay, IV = implied vol. Greeks computed via Black-Scholes from Yahoo IV.
Recent news
- The Real Price of AbbVie Stock Is Cheaper Than You Think4h ago
- AbbVie Has Raised Its Dividend for 53 Straight Years and Still Looks Attractively Valued. Is This Dividend King the Smartest Buy in Healthcare Right Now?5h ago
- AbbVie (ABBV) Stock May Be Mispriced On Its 172% Run13h ago
- AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata15h ago
- AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo15h ago
- Rick Scott Warns Beijing's New Drug Rules Could Threaten US Medicine Supply: 'Stop Being Dependent on Communist China'15h ago
- Goldman Sachs uncovers key AbbVie stock signals before earnings18h ago
- What Johnson & Johnson Stock Told You Before It Surged1d ago
- Does Eli Lilly Stock Actually Diversify Your Portfolio?1d ago
- Botox Maker Tops Buy Point, But Here Comes The Earnings Report1d ago
- 3 Major Reasons for Investors to Buy AbbVie Stock Before July 31st1d ago
- Should You Buy, Hold or Sell ABBV Stock Ahead of Q2 Earnings?1d ago
Reference data only. Not a recommendation. Greeks and expected-move figures are estimates, not certainties. You confirm all entries and contracts in TradingView and Charles Schwab.